Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival. METHODS: We randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods. RESULTS: A total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P = 0.00973 by log-rank test). The survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The time from randomization to disease progression during receipt of second-line therapy or to death was also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.55 to 0.87). CONCLUSIONS: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in view of the OS benefit seen in several trials,36, 37, 38, 39, 40, 41, 42 both in the first- and second-line settings”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“the combination of tamoxifen and ribociclib led to increased cardiotoxicity (arrhythmia)”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Self-citationOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSlamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Self-citation
Cited by
Items 501–600 of 1,000
CDK4/6 inhibitors in breast cancer – fromin vitromodels to clinical trials
Saleh, L., Wilson, C., & Holen, I. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1684559 · Cited by 11
“More recent analysis of the MONALEESA-7 trial was able to assess the overall survival in ribociclib (in combination with endocrine therapy) treated patients [89].”
BackgroundWang, X., Liu, G., Sheng, N., Zhang, M., Pan, X., Liu, S., Huang, K., Cong, Y., Xu, Q., Jia, X., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2018 · Cited by 9
Bayraktar, S., Batoo, S. A., Al‐Hattab, E., Basu, S., Okuno, S. H., & Glück, S. (2020) · Future Oncology · doi:10.2217/fon-2020-0234 · Cited by 10
More efficient and inclusive time-to-event trials with covariate adjustment: a simulation study
Momal, R., Li, H., Trichelair, P., Blum, M. G. B., & Balazard, F. (2023) · Trials · doi:10.1186/s13063-023-07375-0 · Cited by 8
“HR+ metastatic breast cancer in premenopausal patients (mBC) MONALEESA-7 [35] Ribociclib vs placebo in addition to endocrine therapy Probability of death at 3.”
BackgroundHartkopf, A. D., Walter, C. B., Kolberg, H., Hadji, P., Tesch, H., Fasching, P. A., Ettl, J., Lüftner, D., Wallwiener, M., Müller, V., et al. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2286-5372 · Cited by 8
Patel, R., Mathews, J., Hamm, C. M., Kulkarni, S., Gupta, R., Opperman, T., Chiong, J. D., & Nasser, A. (2025) · Current Oncology · doi:10.3390/curroncol32010052 · Cited by 8
New Drugs, New Toxicities: Side Effects of New and Emerging Breast Cancer Therapies
LeVee, A. A., Deutsh, A., Lindgren, E. S., Yan, R., Moore, H., Pasricha, N. D., Leventhal, J. S., Dent, S. F., & Rugo, H. S. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473384 · Cited by 11
Sun, C., Hu, D., Peng, W., Cui, Z., & Lin, Y. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04099-0 · Cited by 9
Duchnowska, R., Soter, K., Pogoda, K., Smok-Kalwat, J., Grela-Wojewoda, A., Winsko-Szczęsnowicz, K., Kowalewska-Felczak, A., Szwiec, M., Danielewicz, I., Streb, J., et al. (2025) · The Breast · doi:10.1016/j.breast.2025.104665 · Cited by 8
Zhou, J., Lin, X., Wang, S., Xie, M., Hu, X., & Cai, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1673284 · Cited by 8
Alves, C. L., Karimi, L., Terp, M. G., Jakobsen, M. K., Zhou, F. H., Policastro, B., Nissen, N., Johansen, L. E., Ravnsborg, T., Eshraghi, L., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adp5088 · Cited by 11
Stellato, D., Thabane, M. E., Chandiwana, D., Park, J., & Delea, T. E. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01028-3 · Cited by 8
“2018 data cut-off, which represent the final per-protocol efficacy results [15].”
BackgroundBurne, R. M., Balu, S., Guérin, A., Bungay, R., Sin, R., & Paul, M. L. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1939705 · Cited by 9
Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer
Müller, V., Welslau, M., Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., Fehm, T. N., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1811-6148 · Cited by 9
Self-citationZhou, Y., Zhou, J., Xiao, J., Wang, Y., Wang, H., Shi, H., Yue, C., Jia, F., Li, P., Hu, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.866293 · Cited by 8
“Due to the rapid advancement of targeted therapy, the combination of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with firstline endocrine therapy has been used in late-stage development, but a large portion of patients may not benefit from the treatment (4, 9).”
BackgroundStanciu, I.-M., Pirlog, C. F., Anghel, A. W., Paroșanu, A. I., Olaru, M., Orlov-Slavu, C. M., Iaciu, C. I., Popa, A. M., Vrabie, R. C., & Niţipir, C. (2023) · Medicina · doi:10.3390/medicina59040696 · Cited by 9
“8% of the patients in the ribociclib group [16].”
BackgroundAvailable Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases
Rader, R. K., Anders, C. K., Lin, N., & Sammons, S. L. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01086-z · Cited by 8
“Ribociclib added to AIs in the first-line setting improves OS in both premenopausal and postmenopausal women [16, 17].”
BackgroundVilla, F., Crippa, A., Pelizzoni, D., Ardizzoia, A., Scartabellati, G., Corbetta, C., Cipriani, E., Lavitrano, M., & Ardizzoia, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914427 · Cited by 10
“…trials have demonstrated substantial clinical benefit from the use of CDK4/6 inhibitors (CDK4/6is) (palbociclib, ribociclib and abemaciclib) in the first-line setting for metastatic hormone receptor HR+/HER2 − disease, with a substantial improvement in progression-free survival (PFS) [9–12].”
Assad, D. X., Morelle, A. M., de Brito, M. L., Paes, F. R., Mattar, A. P. L., Leal, J. H. S., Simon, S. D., Lima, E. M. A., Werutsky, G., Piotto, G. H. M., et al. (2024) · JCO Global Oncology · doi:10.1200/go.23.00484 · Cited by 11
“It is estimated to reduce the risk of death between 24% 11 and 29%, 13 with median overall survival reaching 63.9 months.”
BackgroundInfluentialO’Connor, T. N., Schultz, E., Wang, J., O’Connor, T. L., Levine, E. G., Knudsen, E. S., & Witkiewicz, A. K. (2024) · Cancers · doi:10.3390/cancers16091749 · Cited by 11
Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma
Dong, L., Liu, C., Sun, H., Wang, M., Sun, M., Zheng, J., Yu, X., Shi, R., Wang, B., Zhou, Q., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216956 · Cited by 9
Schneeweiss, A., Brucker, S. Y., Huebner, H., Volmer, L. L., Hack, C. C., Seitz, K., Ruebner, M., Heublein, S., Thewes, V., Lüftner, D., et al. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2286-6066 · Cited by 8
Büyükbayram, M. E., Hannarici, Z., Düzköprü, Y., Turhan, A., Çağlar, A. A., Eşdur, P. Ç., Bilici, M., Tekin, S. B., & Yazılıtaş, D. (2024) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s464161 · Cited by 9
Nabieva, N., Brucker, S. Y., & Gmeiner, B. (2024) · Cancers · doi:10.3390/cancers16244163 · Cited by 9
Jeong, J. H., Kim, J. E., Ahn, J., Jung, K. H., Koh, S., Cheon, J., Sohn, J., Kim, G. M., Lee, K. S., Sim, S. H., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.044 · Cited by 8
Self-citationJeong, H., Jeong, J. H., Kim, J. E., Ahn, J., Jung, K. H., Koh, S., Cheon, J., Sohn, J., Kim, G. M., Lee, K. S., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33613 · Cited by 9
Self-citationDavie, A. M., Carter, G. C., Rider, A., Bailey, A., Lewis, K., Price, G., Ostojic, H., Ringeisen, F. P., & Pivot, X. B. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100226 · Cited by 11
Dawood, S. S., Konstantionva, M., Dent, R. A., Perazzo, F., Kim, S., Villarreal-Garza, C. M., Franco, S., Dai, M., & Simon, S. D. (2021) · BMC Proceedings · doi:10.1186/s12919-021-00224-5 · Cited by 10
“Further, ribociclib and abemaciclib have also shown overall survival (OS) benefit in combination with endocrine therapy in separate trials [40, 42, 43].”
BackgroundMethodNCCN Guidelines Updates: Management of Patients With HER2-Negative Breast Cancer
Gradishar, W. J. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.5016 · Cited by 9
Exploring new pathways in endocrine-resistant breast cancer
de Pinho, I. S., Abreu, C., Gomes, I., Casimiro, S., Pacheco, T. R., Sousa, R., & Costa, L. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00086 · Cited by 9
Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer
Aktas, B., Fehm, T. N., Welslau, M., Müller, V., Lüftner, D., Schütz, F., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1912-7362 · Cited by 8
Self-citationBullous Skin Rash: A Rare Case of Palbociclib-Induced Dermatological Toxicity
Khan, N. A. J., & Alsharedi, M. F. (2020) · Cureus · doi:10.7759/cureus.10229 · Cited by 8
“All CDK 4/6 inhibitors in combination with aromatase inhibitors are standard-of-care first-line agents in metastatic HR+ breast cancer [4-6].”
BackgroundLoke, L., Lee, S. C., Pearce, F., Ng, K., & Aziz, M. I. A. (2020) · Cancer Reports · doi:10.1002/cnr2.1308 · Cited by 11
“The impact of these differences on survival is unknown and although we modeled the impact of using local treatment mixes on treatment costs, we did not change the survival curves which were based on MONALEESA-7.”
BackgroundInfluentialTakada, S., Maeda, H., Umehara, K., Kuwahara, S., YAMAMOTO, M., Tomioka, N., Watanabe, K., & Mino, K. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00187 · Cited by 8
Armand, J., Kim, S., Kim, K., Son, E., Kim, M., Kalinsky, K. M., & Yang, H. W. (2025) · eLife · doi:10.1101/2024.11.11.623139 · Cited by 9
Andujar, J. M. C., de la Peña, F. A., Vila, M. M., Pascual, J., Tolosa, P., Pages, C., Cuenca, M., & Zotano, Á. G. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.169 · Cited by 15
Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment
Ballestín, S. S., Labena, M. A., Avedillo-Salas, A., Continente, C. M., Blázquez, M. A., & Bartolomé, M. J. L. (2025) · Cancers · doi:10.3390/cancers17050760 · Cited by 8
“In patients ≥ 40 years old, the median OS was 58.8 months in the ribociclib group, compared with 51.7 months in the placebo group, though this difference was not statistically significant (HR: 0.81; 95% CI [0.62–1.07]) [15,16].”
InfluentialBaird, R. D., Bermejo, B., Ruíz-Borrego, M., Vaklavas, C., Moreno, I., Oliveira, M., Armstrong, A. C., Turner, N. C., Incorvati, J., Twelves, C. J., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1198 · Cited by 8
“All three of these CDK4/6i have been shown to be highly effective in combination with ET in early (9, 10) and/or advanced (11–24) disease.”
Cardoso, F., Jacot, W., Küemmel, S., Gupta, S., Cruz, F. M., Balaraman, R., Ferreira, A. F., Ahola, T. M., Станиславовна, Ч. Я., Zhukova, L., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.3687 · Cited by 11
Roussel-Simonin, C., Fernández-Martínez, A., Postel-Vinay, S. C., Mosele, F., Viansone, A. A., Massard, C., Mouren, A., Vibert, J., & Pistilli, B. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00858-0 · Cited by 9
“Amongthesestrategies,targetedtherapies, suchasCDK4/6inhibitors 3 – 5 and PI3K/AKT/Mtor inhibitors 6,7 , and following treatment strategies including novel antibody-drug conjugates (ADCs), like Trastuzumab Deruxtecan 8 and Sacituzumab Govitecan 9,10 , have substantially improved survival outcomes…”
CDK4/6 Dependence of Cyclin D1–Driven Parathyroid Neoplasia in Transgenic Mice
Costa‐Guda, J., Corrado, K. R., Bellizzi, J., Romano, R., Saria, E. A., Saucier, K., Rose, M. M., Shah, S., Alander, C. B., Mallya, S. M., et al. (2020) · Endocrinology · doi:10.1210/endocr/bqaa159 · Cited by 8
Go, M., Noguchi, Y., Masuda, R., Asano, H., Kimura, M., Usami, E., & Yoshimura, T. (2024) · International Journal of Cancer · doi:10.1002/ijc.34962 · Cited by 7
Lim, S. H., Lee, S.-Y., Hong, J. Y., Lee, J., & Kim, S. T. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-20 · Cited by 9
“Ribociclib is an orally bioavailable and highly selective CDK4/6 targeting agent that exhibits an IC 50 value in the low nanomolar range and is often used in combination with endocrine therapy in breast cancer (16).”
Abdel‐Razeq, H., Sharaf, B., Khater, S., Baidoun, H., Hani, H. B., Taqash, A., Khatib, O. E., Edaily, S., Abunasser, M., Tamimi, F., et al. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s479153 · Cited by 10
Leone, J. P., Cole, B. F., Regan, M. M., Thurlimann, B. J. K., Coates, A. S., Rabaglio, M., Giobbie‐Hurder, A., Gelber, R. D., Ejlertsen, B., Harvey, V. J., et al. (2020) · Cancer · doi:10.1002/cncr.33318 · Cited by 7
“23 1 45 (15) 34 (12) 26 (15) 20 (13) 2 142 (47) 121 (42) 72 (44) 83 (54) 3 62 (21) 64 (22) 43 (25) 29 (19) Unknown 53 (18) 66 (23) 29 (17) 22 (14) Nodal status, No.”
Self-citationUpdate Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers
Ditsch, N., Stickeler, E., Behrens, A. S., Belleville, E., Fasching, P. A., Fehm, T. N., Hartkopf, A. D., Jackisch, C., Janni, W., Kolberg‐Liedtke, C., et al. (2021) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1464-1221 · Cited by 8
“This has now been undertaken through a pooled analysis of the MONALEESA trials (MONA-LEESA-2 [22], MONALEESA-3 [23,24], MONALEESA-7 [25,26]) [27].”
Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier
Witt, J. S., Wisinski, K. B., & Anderson, B. M. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.11.019 · Cited by 7
Wyld, L., Reed, M., Collins, K., Ward, S. E., Holmes, G. R., Morgan, J. L., Bradburn, M. J., Walters, S. J., Burton, M., Lifford, K., et al. (2022) · Programme Grants for Applied Research · doi:10.3310/xzoe2552 · Cited by 12
Brazilian breast cancer patient-reported outcomes: What really matters for these women
Silva, A. S., França, A. C. W., Padilla, M. P., Macedo, L. S. D. N., Magliano, C. A. D. S., & Santos, M. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2022.809222 · Cited by 7
“Northeast Region Fortaleza, CE 0 22 (12) Caucaia, CE 0 2 (1)”
Frassoldati, A., Biganzoli, L., Bordonaro, R., Cinieri, S., Conte, P., Laurentis, M. D., Mastro, L. D., Gori, S., Lauria, R., Marchetti, P., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0942 · Cited by 7
Targeted therapy: twenty years of success and failures
Tyulyandin, S. А. (2019) · Practical oncology · doi:10.31917/2004274 · Cited by 10
Hill, A., Gutierrez, E., Liu, J., Sammons, S. L., Kimmick, G. G., & Sedrak, M. S. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00758-x · Cited by 7
Stellato, D., Thabane, M. E., Park, J., Chandiwana, D., & Delea, T. E. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01027-4 · Cited by 7
CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?
Wolff, A. C. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02688 · Cited by 7
Update Breast Cancer 2024 Part 3 – Patients with Advanced Stage Breast Cancer
Lüftner, D., Kolberg, H., Hartkopf, A. D., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Jackisch, C., Marmé, F., et al. (2025) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2515-2366 · Cited by 7
Self-citationAboud, K., Meissner, M., & Jones, R. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251358947 · Cited by 7
Liver X receptors induce antiproliferative effects in basal‐like breast cancer
Haugen, M. H., Gythfeldt, H. V. D. L., Egeland, E. V., Normann, L. S., Pandya, A. D., Vedin, L., Juell, S., Tenstad, E. M., Øy, G. F., Kristian, A., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13476 · Cited by 7
Dinkel, J., Kneidinger, N., & Tarantino, P. (2024) · Insights into Imaging · doi:10.1186/s13244-024-01771-z · Cited by 8
Cánovas, M. S., Robles, J. L., Adoamnei, E., Lavín, D. C., Díaz‐Pedroche, C., Coma, E., Quintanar, T., Verdejo, F. J. G., Solís, M. C., Adrián, S. G., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.08.005 · Cited by 7
Ribociclib-induced autoimmune-like hepatitis: a case report
Kavgacı, G., Şahin, T. K., Sökmensüer, C., Balaban, H. Y., & Aksoy, S. (2024) · Journal of Chemotherapy · doi:10.1080/1120009x.2024.2433368 · Cited by 6
Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer
Janni, W. J., Kolberg, H., Hartkopf, A. D., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Jackisch, C., Marmé, F., et al. (2025) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2533-2783 · Cited by 6
Self-citationLetrozole and Palbociclib in Advanced Breast Cancer: Outcome from Cancer Institute, Chennai
Gnanaguru, V., Dhanushkodi, M., Radhakrishnan, V. S., Kalaiyarasi, J. P., Mehra, N., Joshi, A., Rajan, A. K., Selvarajan, G., Karunakaran, P., Ananthi, B., et al. (2020) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_156_19 · Cited by 6
“Recently, it was shown that ribociclib with hormonal therapy improved the overall survival (OS) by 24% as compared to only hormonal therapy.[12] The advantages of CDK 4/6 inhibitors are oral therapy and manageable toxicity profile.”
BackgroundJacobson, A. (2022) · The Oncologist · doi:10.1093/oncolo/oyac010 · Cited by 6
Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer
Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Kolberg‐Liedtke, C., Kolberg, H., Thomssen, C., Müller, V., Fehm, T. N., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1724-9569 · Cited by 6
Wang, T., Shen, G., Li, J., Huo, X., Wang, M., Liu, Z., Zhao, F., Ren, D., & Zhao, J. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230407101128 · Cited by 8
An Overview of the Roles of CDK4/6 Inhibitors in Metastatic Breast Cancer Elderly Patients
Pacilio, C., Rosati, G., Crispo, A., Bimonte, S., Rella, F. D., Nuzzo, F., & Laurentiis, M. D. (2023) · In Vivo · doi:10.21873/invivo.13228 · Cited by 8
Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls
Wright, K., Mittal, A., & Gyawali, B. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000984 · Cited by 6
Liang, X., Zhang, L., Gui, X., Di, L., Li, H., & Song, G. (2024) · Cancer · doi:10.1002/cncr.35174 · Cited by 6
Orlandi, A., Iattoni, E., Pizzuti, L., Fabbri, A., Botticelli, A., Dio, C. D., Palazzo, A., Garufi, G., Indellicati, G., Alesini, D., et al. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040291 · Cited by 6
Dhakal, A., Falkson, C. I., & O'Regan, R. M. (2021) · Cancer · doi:10.1002/cncr.33650 · Cited by 7
“2% and 46% at 42 months of follow- up for ribociclib- treated and control groups, respectively).(12) In 3 other randomized phase 3 trials (PALOMA 3, MONALEESA 3, and MONARCH 2), each of the 3 CDK4/6 inhibitors, given in combination with fulvestrant, yielded significant improvements in PFS in comparison with fulvestran…”
BackgroundClinical Trials and Breast Cancer Disparities
Bea, V. J., Taiwo, E. O., Balogun, O., & Newman, L. A. (2021) · Current Breast Cancer Reports · doi:10.1007/s12609-021-00422-2 · Cited by 6
Landmark trials in the medical oncology management of metastatic breast cancer
Lu, P., Santa-Maria, C. A., Ballinger, T. J., & Sheng, J. Y.-S. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.06.003 · Cited by 7
Sammons, S. L., Sedrak, M. S., & Kimmick, G. G. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00748-z · Cited by 9
“In the metastatic setting, addition of CDK4/6 inhibitors (abemaciclib, palbociclib, ribociclib) to endocrine therapy has prolonged progression-free and overall survival and has changed practice for these patients [171].”
BackgroundTripathy, D., Curteis, T., Hurvitz, S. A., Yardley, D. A., Franke, F. A., Babu, K. G., Wheatley‐Price, P., Im, Y., Pencheva, R., Eddowes, L. A., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221081203 · Cited by 7
Self-citationBofill, J. S., Antón, F. M., Sanchez, C. A. R., Calvo, E. G., Melia, C. H., Gil, E. M. C., Vidal, M. J., Jiménez-Rodríguez, B., de la Cruz‐Merino, L., Martínez-Jáñez, N., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.09.006 · Cited by 7
Hou, X., Wang, Y., Li, C., Lu, Y., Hao, J., Zhao, J., Hou, Y., Yang, X., He, S., & Shi, Y. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.115391 · Cited by 8
Self-citationPotievskaya, V. I., Амалиевич, А. А., Болотина, Л. В., Королева, Л. А., & Каприн, А. Д. (2021) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2021-20-5-138-148 · Cited by 5
Khanikar, D., Kamalasanan, K., Krishnamurthy, A., Hazarika, M., & Kataki, A. C. (2022) · Springer eBooks · doi:10.1007/978-981-19-5860-1_10 · Cited by 8
Önner, H., Eren, O. Ö., Körez, M. K., Yılmaz, F., & Gedi̇k, G. K. (2023) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2023.04.001 · Cited by 5
Zattarin, E., Mariani, L., Menichetti, A., Leporati, R., Provenzano, L., Ligorio, F., Fucà, G., Lobefaro, R., Lalli, L., Vingiani, A., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204857 · Cited by 5
“5,6 , 8– 11 The most acknowledged antitumor mechanism of CDK4”
BackgroundHormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs
Ke, C., Lin, C., & Lin, C.-S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020732 · Cited by 6
Jiang, H., Zhong, J., Wang, J., Song, G., Di, L., Shao, B., Zhang, R., Liu, Y., Zhu, A., Wang, N., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7249 · Cited by 5
Yayli, G., Tokofsky, A., & Nayar, U. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1461190 · Cited by 5
Brown, N. L., Tivey, A., Frank, S., Phua, S. C., Johnson, J. E., Armstrong, A. C., Wilson, C., Raby, S., Low, S., Hulmes, Y., et al. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.12.001 · Cited by 6
Kindt, C. K., Ehmsen, S., Traynor, S., Policastro, B., Nissen, N., Jakobsen, M. K., Hundebøl, M. F., Johansen, L. E., Bak, M., Arbajian, E., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1497093 · Cited by 5
Imbimbo, G., Pellegrini, M., Scagnoli, S., Pisegna, S., Rizzo, V., Gallicchio, C., Botticelli, A., & Molfino, A. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.02.031 · Cited by 5
Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases
Sanchez, C. G., Domínguez, F., Galindo, H., Mauricio Camus, A., David Oddó, B., Villarroel, A., Razmilic, D., V, Peña, J., Navarro, M. E., Medina, L., et al. (2020) · Revista médica de Chile · doi:10.4067/s0034-98872020000901233 · Cited by 5
Filizoğlu, N., Özgüven, S., & Erdıl, T. Y. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004177 · Cited by 5
Gouton, É., Louis, T., Micallef, J., Meskine, A., Sabatier, R., Cécile, M., Braticevic, C., Gonçalvès, A., Viret, F., Rouby, F., et al. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.64 · Cited by 5
Miyahara, K., Narui, K., Uemura, Y., Yamada, A., Araki, K., Fujisawa, F., Nakayama, T., Ishikawa, T., Taira, N., Kikawa, Y., et al. (2022) · World Journal of Oncology · doi:10.14740/wjon1511 · Cited by 5
“Moreover, abemaciclib and ribociclib in combination with hormonal therapy have significantly prolonged overall survival (OS) [9-11].”
BackgroundBender, L., Pflumio, C., Trensz, P., Pierard, L., Kalish‐Weindling, M., Fischbach, C., & Petit, T. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100738 · Cited by 8
Horani, M., & Abdel‐Razeq, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1272602 · Cited by 6
Alves, N. R., Duarte, A. F., Ribeiro, D. F., Silva, R. S., Carvalho, B. A., & Costa, D. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1286910 · Cited by 5
Kulkarni, A., & Singh, J. C. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2341810 · Cited by 5
“In the MONALEESA-7 Trial, ribociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall survival (OS) benefit in premenopausal and perimenopausal patients with HR-positive HER2-negative advanced breast cancer [3,12].”
BackgroundSchmiester, L., Brasó‐Maristany, F., González‐Farré, B., Pascual, T., Gavilá, J., Tekpli, X., Geisler, J., Kristensen, V. N., Frigessi, A., Prat, A., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0244 · Cited by 6
Shao, Z.-M., Tong, Z., Liu, Q., Li, W., Cai, L., Shen, K., Li, H., Wang, C., Yang, J., Song, Z., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7408 · Cited by 5
Chan, A., Gill, J., Chih, H., Wright, S. C. E., Vasilevski, N., & Eichhorn, P. J. A. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00274 · Cited by 5
Kamaraju, S., Fowler, A. M., Tarima, S. S., Chaudhary, L. N., Burkard, M. E., Giever, T. A., Cheng, Y. C., Parkes, A. M., Lange, C. A., Pipp-Dahm, M., et al. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.11.019 · Cited by 6
Le, D., Speers, C. H., Thompson, L., Gondara, L., Nichol, A., & Lohrisch, C. A. (2019) · Cancer · doi:10.1002/cncr.32631 · Cited by 5
“00973); however, 60% of this study population had not received prior adjuvant endocrine therapy.(22) In the S0226 study looking at first-line anastrozole with or without fulvestrant in postmenopausal women with HR-positive/HER2negative MBC, an OS benefit was seen in the combination arm (hazard ratio, 0.”
BackgroundAdvances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence
Theresa Wicklin Gillespie, R. (2020) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2020.11.1.5 · Cited by 7
“…AI compared to 40.9 months for endocrine therapy alone in pre-/perimenopausal women as initial treatment (hazard ratio (HR), 0.712; Hurvitz et al., 2019), with an estimated OS at 42 months of 70.2% in the ribociclib group and 46.0% in the placebo group (HR, 0.71; Im et al., 2019).”
Influential
Metadata
- Authors
- Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., Villanueva-Vazquez, R., Jung, K.-H., Chakravartty, A., Hughes, G., Gounaris, I., Rodriguez-Lorenc, K., Taran, T., Hurvitz, S., & Tripathy, D.
- Affiliations
- Seoul National University (KR)
- Harvard University (US)
- From Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), the Yonsei Cancer Center, Yonsei University Health System (J.S.), and the Asan Medical Center, University of Ulsan College of Medicine (K.-H.J.), Seoul, and the Center for Breast Cancer, National Cancer Center, Gyeonggi-do (K.-S.L.) — all in South Korea; National Taiwan University Hospital, Taipei, Taiwan (Y.-S.L.); Massachusetts General Hospital Cancer Center and Harvard...
- Novartis (Switzerland) (CH)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 307-316
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2948069739
- Cited by
- 1,001
- References
- 32
- Citations by year
- 2026: 68 · 2025: 119 · 2024: 121 · 2023: 152 · 2022: 159 · 2021: 165 · 2020: 174 · 2019: 42
- FWCI
- 100.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ribociclib, CDK4/6 inhibitors, endocrine therapy, hormone receptor-positive breast cancer, HER2-negative breast cancer, overall survival, aromatase inhibitors, goserelin, tamoxifen, progression-free survival, disease progression, second-line therapy, antineoplastic therapy, treatment-related adverse events, neutropenia
- MeSH terms
- Adult, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Follow-Up Studies, Humans, Middle Aged, Purines, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Survival Analysis, Premenopause, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinases, Aromatase Inhibitors, Protein Kinase Inhibitors, Perimenopause, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.